Our CSO Tanja Ilmarinen will be in Boston on December 11-12 at the International Society for Stem Cell Research Symposium on Pluripotent Stem Cell Therapies. Tanja will be sharing our latest developments from our lead asset STE-101, an off-the-shelf iPS cell derived therapy aimed to cure Limbal Stem Cell Deficiency.

We are excited to be invited as part of this esteemed program featuring pioneers of the industry! For the star line-up, see the program here.

StemSight's COO and co-founder Anni Mörö steps down from active role with StemSight due to personal reasons. Choosing to focus on her academic work and spending more time with her three daughters, she remains a firm supporter of StemSight's work - and we hope to welcome her back when the time is right.

We are excited to welcome Charlotta Backman to StemSight as Head of Clinical Development. Charlotta brings her broad expertise on clinical development at the time when StemSight starts preparing for its transition from the pre-clinical setting to the clinic.

Mytos, a biotechnology company automating cell manufacturing, StemSight and two other cell therapy developers announced collaborations aiming to increase the scalability and cost-efficiency of cell therapy manufacturing. The announcement was covered by Endpoint News.